Related Experiment Video
Updated: Mar 8, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.3K
Implementing Genomic Clinical Decision Support for Drug-Based Precision Medicine
R R Freimuth1, C M Formea2, J M Hoffman3
1Department of Health Sciences Research, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.
CPT: Pharmacometrics & Systems Pharmacology
|January 22, 2017
Summary
Genomic data is rapidly expanding, requiring new tools for personalized medicine. Integrating this information into electronic health records is crucial for effective clinical decision support.
Area of Science:
- Biomedical Research
- Genomics
- Pharmacogenomics
Background:
- Patient-specific genomic data is growing exponentially, impacting drug therapy.
- Personalized medicine (PM) requires actionable genomic insights integrated into clinical workflows.
Discussion:
- Electronic health records (EHRs) need enhanced informatics infrastructure.
- Clinical decision support (CDS) systems must evolve to interpret and apply complex genomic data.
- Integrating diverse genomic datasets presents significant informatics challenges.
Key Insights:
- Actionable genomic information is essential for implementing personalized medicine.
- Robust CDS methods are necessary for translating genomic data into clinical practice.
- The integration of patient-specific genomic data into EHRs is a critical bottleneck.
Outlook:
- Future biomedical research will be defined by patient-specific genomic information.
- Development of advanced informatics infrastructure is key to realizing the potential of genomic medicine.
- Enhanced CDS and EHR integration will enable widespread adoption of personalized drug therapy.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
01:29Pharmacogenetics and Pharmacogenomics: Overview
102
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
102
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
77
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
77
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:27Pharmacogenetics of Drug Metabolism: Overview
77
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60